usual administration of exogenous recombinant FSH
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anovulation
Conditions
Anovulation
Trial Timeline
Nov 1, 2003 → Jan 1, 2007
NCT ID
NCT00492882About usual administration of exogenous recombinant FSH
usual administration of exogenous recombinant FSH is a pre-clinical stage product being developed by Organon for Anovulation. The current trial status is completed. This product is registered under clinical trial identifier NCT00492882. Target conditions include Anovulation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00492882 | Pre-clinical | Completed |
Competing Products
3 competing products in Anovulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MSJ-0011 + urinary hCG (u-hCG) + Follitropin alpha | Merck | Phase 3 | 77 |
| Orlistat Vs Metformin | Roche | Pre-clinical | 23 |
| Follitropin beta | Organon | Pre-clinical | 18 |